Thanks, Don, and good morning, everyone. As Don highlighted, total net sales in the first quarter were $406 million, a 39% increase over Q1 last year and an all-time record high for our company. Foreign exchange adversely impacted sales by 5% in the quarter. So at historical rates, the growth would have been even more impressive. The gross margin rate in Q1 was 7.2%, a 190 basis point improvement compared to the first quarter of fiscal 2022, with our record sales driving a higher level of absorption this year versus a year ago when production was more significantly curtailed by part shortages. Adjusted selling and administrative expenses in the quarter were $16 million compared to $12.3 million in Q1 last year. The increase resulted from higher salary and related payroll costs, stock-based compensation, factoring fees associated with our accounts receivables and travel expense. When measured as a percentage of net sales, however, adjusted selling and administrative expenses were 3.9%, a 30 basis point improvement compared to Q1 last year. Adjusted operating income for the first quarter was $13.3 million or 3.3% of net sales, which compares to last year's Q1 adjusted results of $3.3 million or 1.1% of net sales. While adjusted operating income was outside of our guidance range, it did meet our expectations for stair-steps fiscal year as we ramp up new productions and grow into our close, so to speak, with new expansions in Thailand and in Mexico. We fully expect OI margin to improve over the remainder of the year. Other income and expense increased slightly with expense of $1.4 million in the first quarter of this year versus expense of $1.2 million in Q1 of fiscal 2022. The effective tax rate in Q1 was 21.9% compared to 27.4% in the first quarter last year. Net income in the first quarter of fiscal of 2023 was $9.5 million or $0.38 per diluted share compared to adjusted net income in Q1 of last year of $1.5 million or $0.06 per diluted share. Now turning to the balance sheet. Cash and cash equivalents at September 30, 2022, were $19.7 million. Cash flow used by operating activities in the quarter was $60.2 million, and cash conversion days were 99 days, up from 73 days in the first quarter of last year. Our cash flow and CCD results were driven by increase in inventory, which was up $187.4 million from a year ago and $53.9 million from last quarter. We continue to purchase materials not impacted by the part shortages so that we can fulfill customer orders once the components in short supply are received. It is also important to highlight, however, that the increase in inventory is heavily concentrated in Mexico and Thailand. The facilities were recent expansions have doubled our footprint and manufacturing capacity. We expect inventory turns measured as production-based sales on hand to normalize as the part shortage abates and our expansions continue to ramp. But the absolute dollar level of inventories will likely be higher than levels in the past to support stepped-up production volume. Capital expenditures in the first quarter were $19 million, largely in support of our facility expansion in Poland, equipment for the recently completed expansion in Mexico and capital deployed to support the healthy funnel of new product introductions and equipment with leading-edge technologies and capabilities. Borrowings on our credit facilities at September 30, 2022, were $232.5 million compared to $72.6 million a year ago and $180.6 million at the end of fiscal 2022. Our short-term liquidity available represented as cash and cash equivalents plus the unused amount of our credit facilities, totaled $113.4 million at September 30, 2022. There were no shares repurchased in the first quarter of fiscal 2023. Since October 2015, under our Board authorized share repurchase program, a total of $88.8 million has been returned to our shareowners by purchasing 5.8 million shares of common stock. We have $11.2 million remaining on the repurchase program. We do anticipate some share repurchase in the fiscal year, equal to the stock-based compensation in order to keep our share count flat. As Don noted, we are affirming our guidance for fiscal year 2023 and expect full year results to be at the high end of the range, with net sales of $1.6 billion to $1.7 billion, a 19% to 26% increase year-over-year. Operating margin of 4.6% to 5.2% and capital expenditures totaling $80 million to $100 million. Just to reiterate a point made in Don's opening remarks, new customers and product start-ups can cause margin dilution early in the life cycle. As programs mature and volumes ramp, cost efficiencies are gained. With the increased launch activity due to facility expansions over the last 12 months, there has been near-term pressure to profitability, but we fully expect this to be recovered. As a result, our guidance anticipates sequential improvement in fiscal 2023, which -- with each quarter expected to improve over the previous one. With that, I'll now turn the call back over to Don.